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Summary
Background Time delay between onset of symptoms and seeking medical attention is a major determinant of mortality 
and morbidity in patients with acute coronary artery occlusion. Response time might be reduced by reliable self-
detection. We aimed to formally assess the proof-of-concept and accuracy of self-detection of acute coronary artery 
occlusion by patients during daily life situations and during the very early stages of acute coronary artery occlusion.
Methods In this multicentre, observational study, we tested the operational feasibility, specificity, and sensitivity of our 
RELF method, a three-lead detection system with an automatic algorithm built into a mobile handheld device, for 
detection of acute coronary artery occlusion. Patients were recruited continuously by physician referrals from three 
Belgian hospitals until the desired sample size was achieved, had been discharged with planned elective percutaneous 
coronary intervention, and were able to use a smartphone; they were asked to perform random ambulatory self-
recordings for at least 1 week. A similar self-recording was made before percutaneous coronary intervention and at 
60 s of balloon occlusion. Patients were clinically followed up until 1 month after discharge. We quantitatively assessed 
the operational feasibility with an automated dichotomous quality check of self-recordings. Performance was assessed 
by analysing the receiver operator characteristics of the ST difference vector magnitude. This trial is registered with 
ClinicalTrials.gov, number NCT02983396.
Findings From Nov 18, 2016, to April 25, 2018, we enrolled 64 patients into the study, of whom 59 (92%) were eligible 
for self-applications. 58 (91%) of 64 (95% CI 81·0–95·6) patients were able to perform ambulatory self-recordings. Of 
all 5011 self-recordings, 4567 (91%) were automatically classified as successful within 1 min. In 65 balloon occlusions, 
63 index tests at 60 s of occlusion in 55 patients were available. The mean specificity of daily life recordings was 
0·96 (0·95–0·97). The mean false positive rate during daily life conditions was 4·19% (95% CI 3·29–5·10). The 
sensitivity for the target conditions was 0·87 (55 of 63; 95% CI 0·77–0·93) for acute coronary artery occlusion, 
0·95 (54 of 57; 0·86–0·98) for acute coronary artery occlusion with electrocardiogram (ECG) changes, and 1·00 (35 of 
35) for acute coronary artery occlusion with ECG changes and ST-segment elevation myocardial infarction criteria 
(STEMI). The index test was more sensitive to detect a 60 s balloon occlusion than the STEMI criteria on 12-lead ECG 
(87% vs 56%; p<0·0001). The proportion of total variation in study estimates due to heterogeneity between patients 
(I²) was low (12·6%). The area under the receiver operator characteristics curve was 0·973 (95% CI 0·956–0·990) for 
acute coronary artery occlusion at different cutoff values of the magnitude of the ST difference vector. No patients 
died during the study.
Interpretation Self-recording with our RELF device is feasible for most patients with coronary artery disease. The 
sensitivity and specificity for automatic detection of the earliest phase of acute coronary artery occlusion support the 
concept of our RELF device for patient empowerment to reduce delay and increase Survival without overloading 
emergency services.
Funding Ghent University, Industrial Research Fund.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Patient delay during acute coronary artery occlusion is a 
pervasive problem worldwide. It is associated with out-of-
hospital ventricular fibrillation and irreversible loss of 
myocardial viability. According to the global incidence of 
acute myocardial infarction,1 the incidence and risk 
factors of primary ventricular fibrillation,2,3 and the effect 
of treatment delay,4 an estimated 1000 deaths or more a 
day could have been avoided in 2017 by decreasing 
patient delay by 90 min.
A scientific statement from the American Heart 
Association5 describes the sociodemographic, clinical, 
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and social cognitive emotional factors that are associated 
with patient delay during acute coronary artery occlusion 
and advises that health-care providers assist patients with 
coronary artery disease in making anticipatory plans 
for timely recognition and response to an acute event. 
However, even well-informed patients are often undecided 
and left with doubts.5 In an up-and-coming era of patient 
empowerment with digital medical sensors,6 a rapid rule-
in tool (ie, a tool that confirms acute coronary artery 
occlusion without delay) has been proposed as a potential 
strategy to avoid delay during symptoms of acute coronary 
artery occlusion.7
To improve outcome in patients with coronary artery 
disease, such a tool should fulfil some conditions. First, 
during ongoing chest pain the device should first display, 
as a reminder, the individual’s anticipatory plan for 
timely recognition and response to an acute event, which 
was made with their health-care provider. Second, for 
those with doubts or a high threshold for the proposed 
action, the tool should additionally empower the patient 
by a rapid test for acute coronary artery occlusion. Finally, 
the device should be safe and generate a quick automatic 
response at any given time and place because onset of 
symptoms is unpredictable.
We developed over the past 7 years a three-lead system 
and automatic algorithm (RELF method) that can 
accurately detect acute coronary artery occlusion when 
applied by experienced medical personnel.8 We then 
developed the first handheld device for automatic self-
detection of acute coronary artery occlusion. Patients at 
risk of this disorder could carry our device and electrodes 
in their pocket or have them constantly in their vicinity 
to self-apply the RELF method immediately during 
symptoms to avoid delay in case of acute coronary artery 
occlusion. Self-applicability is the most crucial step to 
establish the potential of the device to reduce patient 
delay in the very early phase of acute coronary artery 
occlusion. Therefore, the aim of this study was to 
formally assess the proof-of-concept and accuracy of self-
detection of acute coronary artery occlusion in the hands 
of patients during daily life situations (specificity) and 
during the very early phase of acute coronary artery 
occlusion (sensitivity).
Methods
Study design and participants
In this multicentre observational study, patients with 
planned elective percutaneous coronary intervention 
were recruited at Ghent University Hospital, Ghent, 
Belgium; AZ St-Jan Hospital, Bruges, Belgium; and 
AZ Nikolaas Hospital, Sint-Niklaas, Belgium. Patients 
were included if they were admitted to the hospital with 
Research in context
Evidence before this study
Patient delay is a substantial unsolved problem causing 
avoidable deaths in patients with acute coronary artery 
occlusion. Reliable self-detection of acute coronary artery 
occlusion might reduce patient doubts and delay during ongoing 
chest pain. Invasively placed intracardiac ischaemia monitors 
have been developed for earlier identification of ischaemia in 
patients with a high risk of acute coronary syndrome and alert 
patients of a potential occlusive event. We did a systematic 
literature review of PubMed on Jan 29, 2019, using the search 
terms ((sensitivity OR specificity) AND (infarction OR (acute 
coronary occlusion)) AND (Device)) and found that no 
self-applicable device can accurately detect acute coronary artery 
occlusion non-invasively. We have shown that an automatic 
algorithm based upon a self-applicable three-lead system 
(RELF method) can accurately detect acute coronary artery 
occlusion. We then developed a handheld device for 
self-application of this RELF method.
Added value of this study
This is the first clinical study that supports the proof-of-concept 
of self-detection of acute coronary artery occlusion in outpatients 
with coronary artery disease. Our prospective, multicentre study 
shows that most patients with coronary artery disease who can 
use a mobile phone or smartphone can reliably use our handheld 
device. We illustrate how our device can integrate patient skills 
with anticipatory plans from health-care providers into more 
time-efficient self-triage during chest pain.
Implications of all the available evidence
Monte Carlo simulations that include our study findings 
predict that patients with an annual risk for acute coronary 
artery occlusion of more than 0·5%, who are well informed 
and empowered with a validated device, will be alerted 
without delay during acute coronary artery occlusion. The 
median patient delay during acute coronary artery occlusion 
can potentially decrease to less than 20 min. For 100 patients 
with an acute coronary artery occlusion this could save 
150 quality-adjusted life-years. We provide new data to 
calculate how emergency services will economically benefit 
from the empowered self-triage of the patient with chest 
pain. With the evidence from our study and an expected cost 
of less than €300 for the device, policy makers can calculate 
the economic benefit to empower patients in relation to their 
annual risk for acute coronary artery occlusion. It is feasible to 
assess whether the introduction of the RELF device in the 
management of coronary artery disease will effectively reduce 
patient and system delay. Handheld devices and implantable 
intracardiac ischaemia monitors might be complementary 
solutions to reduce patient delay. Handheld devices are 
targeted for a large population with low or moderately 
increased risk for an acute coronary artery occlusion, whereas 
the implantable monitors are targeted for more selected 
patients at very high risk for acute coronary artery occlusion or 
who have an additional indication to implant an intracardiac 
device.
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angiographically proven significant (>50% diameter 
stenosis) coronary artery disease and were discharged 
with planned elective percutaneous coronary intervention. 
Patients were excluded if they had a pacemaker or 
implantable cardioverter-defibrillator implant, a history of 
coronary artery bypass grafting, an ST-segment elevation 
myocardial infarction (STEMI) within the past 7 days, an 
intolerance for skin electrodes, prolonged hospitalisation 
after diagnostic angiography, and an inability to use a cell 
phone or smartphone in the past month. Patient 
screening for eligibility was performed once a day by the 
study nurse or clinical investigator guided by an updated 
list of planned coronary angiographies. Shortly before 
discharge, patients were invited by the study nurse or 
clinical investigator to participate in the study after a 
10–15 min introduction and demonstration of the RELF 
device. After signing informed consent, a first self-
recording was performed under supervision of the study 
nurse or clinical investigator.
This multicentre clinical trial was approved by the 
central and local ethical committees (Belgium Registration 
Number: B670201628891). The device was approved for 
clinical investigation trial by the Federal Agency for 
Medicines and Health Products (AFMPS/80M0648/). The 
trial is registered with ClinicalTrials.gov (NCT02983396). 
All patients provided written informed consent.
The RELF method and the study device
In a previous clinical study8 we introduced and validated 
the RELF method, which is an easy, self-applicable, three-
lead configuration, with its associated automatic 
algorithm to calculate ST vectors. In brief, the RELF 
leads record the voltage differences from the right 
shoulder (R) to an exploratory electrode (E), to the left 
shoulder (L), and to the left iliac crest (F). The algorithm 
calculates an individualised ST reference vector based on 
the average of the most recent 13 reference measurements 
in asymptomatic daily life conditions. For an index test 
(decision test), it calculates the magnitude of the ST 
difference vector (STDV; the difference between the 
reference vector and the index vector) in an ortho-
normalised coordinate system (STDVn; expressed in 
normalised units [nu]). An a priori-defined cutoff for 
STDVn was set at 2·947 nu, which is the 95th percentile 
of all previously recorded values of healthy participants 
in the previous RELF study.8
The RELF study device consists of a handheld RELF 
recorder with standard self-adhesive skin electrodes 
(appendix). It is a custom-made electrocardiogram (ECG) 
device designed for self-application of the RELF method. 
The device was connected by Bluetooth to the dedicated 
study smartphone, on which the custom-made user 
interface app was installed (and other apps were disabled), 
to start a recording, send data to the study server, and 
receive automated feedback within 1 min. Two feedback 
responses may be generated: either successful recording 
or check electrodes and muscle activity and repeat 
recording. After the final study visit the devices were 
returned for re-use.
Outcomes
We quantitatively assessed the operational feasibility of 
self-recording with an automated dichotomous quality 
check. The quality was not accepted if the interquartile 
range of ST level was above 200 µV for lead RE, above 
100 µV for lead RL, and above 230 µV for lead RF. 
We assessed the accuracy of the device in the hands of 
patients in settings that were most representative for 
intended use. Therefore, we analysed the use of the device 
in daily life situations (specificity) without acute coronary 
artery occlusion (absence of target condition). After 
demonstration of the device functionalities and signing 
informed consent, a device instruction flyer was given to 
the patients. They were asked to perform random self-
recordings at home preferably 5 times a day or more 
for at least 1 week. They were encouraged to remove 
electrodes after each recording and reapply new ones for 
the next recording. A maximum of 12 h of electrode 
application to the body was allowed. Before each recording 
the app requested the patient to indicate the body position 
(standing, lying, or sitting) and the presence or absence of 
physical activity in the past 5 min before the recording. 
After each measurement, the patient received immediate 
automated feedback (appendix) regarding the recording 
quality.
In case of bad electrode contact or noise due to muscle 
activity during a recording, the user received a warning 
on the smartphone within 1 min to check the electrodes 
and relax muscles during the measurement. If a positive 
result was detected, the patient received an automated 
request to do a repeat measurement. The trial safety 
monitor also received the measured data instantaneously 
as a safety precaution in the background of the study.
We analysed the sensitivity of the device for the 
detection of the very early phase of acute coronary artery 
occlusion, simulated by 60 s of coronary balloon occlusion 
(the target condition). In the catheterisation laboratory, 
the patients were requested to make a preprocedural self-
recording similar to a home recording. During the 
percutaneous coronary intervention procedure, the RELF 
device was kept in place and was connected via Bluetooth 
to a laptop for continuous recording. Custom-made 
software on the laptop enabled the study coordinator or 
nurse to mark timestamps corresponding to baseline and 
end of the 60 s balloon occlusion (just before deflation). 
At each given timestamp a 12-lead ECG was recorded 
simultaneously.
All standard 12-lead ECGs were recorded according to 
the European Society of Cardiology guidelines9 and quality 
certificates of ECG equipment were collected. In each 
study centre, at least one study nurse was instructed on 
the standard 12-lead ECG configuration. Printouts of all 
ECGs were collected and the interpreting cardiologists 
were masked to labelling. Five cardiologists independently 
See Online for appendix
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assessed each ECG for presence of ST elevation criteria 
according to the third international definition of myo-
cardial infarction criteria,10 including the ST depression 
criteria for posterior myocardial infarction as STEMI 
equivalent.9 In case of mismatch, the assessment of the 
majority was used for further analysis. Three other 
cardiologists independently assessed ECG pairs consisting 
of unlabelled ECGs at baseline and at 60 s balloon 
occlusion. The ECG pairs were simultaneously presented 
and in random order within pair for the assessment of any 
ECG change. To categorise a pair of ECGs as no change a 
matching between all three cardiologists was mandatory. 
ECGs at 60 s of balloon occlusion were categorised as 
no ECG change compared with baseline, ECG change 
without STEMI criteria, or ECG change with STEMI 
criteria.
Adverse events were collected at each visit during the 
study inclusion period and were reported to the principal 
investigator. 
Statistical analysis
We aimed to include at least 60 balloon occlusions, in 
line with our previous study,8  to compare the sensitivity 
of self-applications with the sensitivity of the RELF 
method as applied by medical personnel.
For paired comparison of STDVn values before and at 
60 s of balloon occlusion, we used the Wilcoxon Signed 
Ranks Test. We dichotomised the RELF tests at a 
prespecified cutoff of 2·947 nu based on the 
95th percentile of all normal STDVn values from our 
previous study.8 We used the McNemar test for paired 
comparison between the dichotomised RELF method 
and the conventional STEMI criteria. p values of less 
than 0·05 were considered statistically significant. We 
calculated boxplot summaries in SPSS Statistics 25. We 
analysed the receiver operating characteristics (ROC) 
curve in SigmaPlot.
We made group and subgroup summaries of the false 
positive rate taking into account the different sample 
sizes of the individuals. We multiplied the individual 
false positive rates with a weight factor that represents 
the individuals’ sample size. Since we assume that 
variability is not only due to sampling error but also to 
variability between patients we used a random effect 
model, for which the weight of the individual false 
positive rate is further adjusted with a constant that 
represents it.11 We conducted the calculations necessary 
for the forest plot, including weighting of cases according 
to sample size and variance, using a previously published 
template.11 Significance for heterogeneity was quantified 
with the I² statistics.12
Role of the funding source
The funder of the study had no role in data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author (FVH) had full access to all 
the data in the study. FVH, MDB, and PG had final 
responsibility for the decision to submit for publication. 
Results
Between Nov 18, 2016, and April 25, 2018, 67 patients 
were invited to participate in the study (figure 1). Three 
Figure 1: Experimental set up for detecting acute coronary artery occlusion
Operational feasibility (upper panels), specificity during daily life conditions (left panels), and sensitivity during 
acute balloon occlusions (right panels) were the main outcomes. ROC=receiver operating characteristics. 
*57 × 13 reference recordings;  one patient performed only 12 reference recordings before angioplasty and one 
patient performed only four reference recordings and therefore no index tests. ICD=implantable cardioverter 
defibrillator. STEMI=ST-segment elevation myocardial infarction criteria.
67 invited
64 enrolled
59 eligible for self-applications
2 believed they were not able to perform 
self-applications
1 found the study too demanding
3 received repeated error feedback at intake
(algorithm for ST level detection failed 
when QRS duration was more than 150 ms)
2 dropped out before angioplasty 
(negative motivation)
67 target vessels and 67 self-applications
before angioplasty
2 no angioplasty (functional 
normal lesions)
2 occlusions with experimental 
failure (battery empty; 
disturbance by charger of 
defibrillator)
63 index tests during balloon occlusion
Sensitivity analysisSpecificity analysis
3810 index tests during daily life conditions
58 with reference library eligible for 
performing index tests
ROC curve analysis
5011 self-applications during daily life 
conditions
444 below automated quality 
score
757 for building 59 reference 
libraries*
Patients with planned elective coronary 
angioplasty who could use a smartphone, 
without a pacemaker or ICD implant, history 
of coronary artery bypass grafting, a STEMI 
within the past 7 days, an intolerance for skin 
electrodes, or prolonged hospitalisation after 
diagnostic angiography
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patients were not enrolled as they believed that they were 
not able to perform self-measurements or that the study 
was too demanding. Thus, 64 patients signed informed 
consent. Patient and baseline ECG characteristics are 
summarised in table 1.
58 (91%) of 64 patients (95% CI 81·0–95·6) were able 
to perform ambulatory self-recordings. Five (8%) patients 
were unable to build their own reference library as the 
algorithm rejected the presence of left bundle branch 
block (n=3) or the patient was not motivated to perform 
self-recordings (n=2; figure 1). One patient had an 
incomplete reference library, including only four 
reference recordings, but was included in the sensitivity 
analysis as he participated with the balloon occlusion 
phase. 59 (92%) patients performed 5011 ambulatory self-
recordings of 12 s each; with a median of 71 recordings 
per patient (IQR 44–102; figure 1). Most patients (68%) 
spontaneously performed more than the requested 
number of measurements, supporting the ease of use of 
the device. Of all 5011 recordings, 4567 (91·1%) were 
immediately and automatically classified as successful 
and the patient received positive confirmation from the 
server within 1 min. The main reason for an unsuccessful 
recording was interfering noise either from unstable 
skin contact of the electrodes or from muscle activity. 
Both have overlapping signal characteristics that were 
not separable by the algorithm. Of all recordings, 
757 (15·1%) were used to build the personal reference 
libraries consisting of 13 successful recordings for each 
individual (one patient had only 12 reference recordings 
before the angioplasty; after discharge, the patient further 
completed the reference library and performed further 
index tests during daily life conditions). As such, 
3810 home recordings were labelled as index tests during 
daily life conditions. After an unsuccessful recording 
(444 [8·9%]), the patient received an automated message 
from the server within 1 min, requesting to check 
electrodes and muscle activity and repeat recording. After 
an unsuccessful recording, all patients performed a repeat 
recording which went on to be successful after one attempt 
in 70% (181/258), two attempts in 14% (37/258), or three 
attempts in 7% (18/258). 22 (0·44%) of all 5011 self-
recordings went on to be successful after more than three 
attempts and were marked as failed.
All 59 patients self-applied the device before entering the 
catheterisation laboratory or immediately after positioning 
on the x-ray table. One patient switched the L and 
F electrodes and another patient accidentally placed the 
F electrode on the right iliac crest. Both wrong applications 
were corrected by the study nurse. All patients performed a 
successful baseline RELF recording in the correct position 
for the percutaneous coronary intervention procedure and 
before local anaesthesia. Simultaneously, a 12-lead ECG 
was recorded. Eight patients had a second lesion planned 
for percutaneous coronary intervention. For each of these 
lesions a new baseline recording with the RELF device and 
12-lead ECG was taken before crossing the percutaneous 
coronary intervention wire through the second lesion. In 
two lesions, no angioplasty was performed because the 
functional assessment of the lesion was not significant. In 
Patients with ambulatory 
self-recordings (n=59)*
Sex
Male 43 (73%)
Female 16 (27%)
Age, years 64·4 (9·7)
Weight, kg 82·6 (14·8)
Height, cm 171·1 (14·8)
Body-mass index, kg/m² 28·2 (5·0)
Atrial fibrillation 3 (5%)
First degree atrioventricular block 3 (5%)
Right bundle branch block 5 (9%)
Left anterior hemiblock 7 (12%)
Right bundle branch block and left 
anterior hemiblock
3 (5%)
Left bundle branch block 0
Q waves 11 (19%)
Any abnormal QRS† 19 (32%)
Data are n (%) or mean (SD). *Five patients who were enrolled but who could not 
carry out self-recordings are not included. †Abnormal QRS was any bundle branch 
block or Q wave. 
Table 1: Patient characteristics
Figure 2: STDVn expressed by home recordings
3810 home recordings were obtained, 94·4% of which were lower than the 
prespecified STDVn cutoff value of 2·947 nu and 5·6% of which were higher than 
the cutoff. nu=normalised units. STDVn=ST difference vector in an 
orthonormalised coordinate system.
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total, 65 lesions were balloon occluded for 60 s (figure 1). At 
60 s of balloon occlusion, a second RELF recording and 
12-lead ECG were taken simultaneously. Two recordings 
at 60 s of balloon occlusion technically failed, one due 
to high frequency interference from the catheterisation 
laboratory’s external defibrillator (unintended charging of 
capacitors) and the second due to low battery of the RELF 
device. Finally, 63 index tests (in 55 patients) at 60 s of 
occlusion were available (figure 1).
The length of the STDVn was used as a decision 
parameter to detect ST elevation with the RELF device. 
The ambulatory self-recorded STDVn measurements 
(n=3810) are summarised in figure 2. The mean value 
was 1·39 nu (SD 0·876) and the median value was 
1·17 nu (IQR 0·80–1·75). The distribution was not 
normal (Kolmogorov-Smirnov 0·109; p<0·00001). The 
90th percentile was 2·49 nu and 95th percentile was 
3·06 nu.
The distribution of the ambulatory self-recordings and 
the recordings in the catheterisation laboratory before 
and at 60 s of balloon occlusion is summarised in figure 3. 
Neither postural changes nor presence of physical activity 
within 5 min before recording, or installing the patient on 
the x-ray table, influenced the distribution of STDVn, 
taking into account that the false positives are excluded 
from the distribution. All outliers are above the 
prespecified cutoff and therefore represent false positive 
recordings (figure 3). Balloon occlusions without 
observed changes in simultaneous 12-lead ECG (n=6) had 
no significant increase of STDVn (paired analysis 
p=0·92). Occlusions with changes in simultaneous 
12-lead ECG but without STEMI criteria (n=22) had a 
highly significant increase of STDVn (paired analysis 
p=0·00005). Occlusions with STEMI criteria on 12-lead 
ECG (n=35) had the highest increase of STDVn (paired 
analysis p<0·00001).
The STDVn values of the 3810 daily life recordings were 
less than the a priori set cutoff of 2·947 nu in 3597 
(94·4%) of 3810 cases. To estimate the mean false positive 
rate we weighted the individual contributions with a 
random effect model meta-analysis (appendix). Barring 
one patient who performed only four measurements, the 
mean false positive rate in 58 patients was 4·19% (95% CI 
3·29–5·10) corresponding to a mean specificity of daily 
life recordings of 0·96 (0·95–0·97).
Figure 3: STDVn of all test recordings according to physical condition
The horizontal line represents the prespecified STDVn cutoff value of 2·947 nu. All STDVn values during ST elevation (occlusions with ECG changes and STEMI criteria, 
n=35) were higher than the cutoff. ECG=electrocardiogram. nu=normalised units. STEMI=ST-segment elevation myocardial infarction. STDVn=ST difference vector in 
an orthonormalised coordinate system. *Extreme outliers. †Wilcoxon Signed Ranks Test for paired comparison of preocclusion and occlusion STDVn values. Note that 
all extreme outliers of the ambulatory self-recordings are higher than the prespecified cutoff and are false positives.
Sitting
(n=2078)
Sitting
after exercise
(n=201)
Standing
(n=784)
Standing
after exercise
(n=147)
Supine
(n=600)
Baseline
preocclusion
(n=63)
Occlusion
without ECG
changes
(n=6)
Occlusion
with ECG
changes and 
no STEMI
criteria
(n=22)
Occlusion
with ECG
changes and
STEMI criteria
(n=35)
0
5
2·947
10
15
20
25
ST
DV
n 
(n
u)
Ambulatory self-recordings
Self-recordings in the catheterisation laboratory p<0·00001†
p=0·00005†
p=0·92†
Total number of 
occlusions
RELF positive RELF negative Sensitivity (95% CI)
Acute coronary artery 
occlusion
63 55 8 0·87 (0·77–0·93)
LAD occlusion 33 30 3 0·91 (0·76–0·97)
RCA occlusion 15 13 2 0·87 (0·62–0·96)
CX occlusion 15 12 3 0·80 (0·55–0·93)
With ECG changes on 
12-lead ECG
57 54 3 0·95 (0·86–0·98)
With STEMI criteria on 
12-lead ECG
35 35 0 1·00* 
Data are number of occlusions. Subgroups are defined by vessel territory or by ECG changes during occlusion. Cutoff for 
RELF positive status was 2·947 normalised units. LAD=left anterior descending artery. RCA=right coronary artery. 
CX=left circumflex artery. ECG=electrocardiogram. STEMI=ST-segment elevation myocardial infarction. *95% CI not 
calculated as sample sensitivity was 1.
Table 2: Sensitivity at 60 s of acute coronary artery occlusion
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All index STDVn at 60 s of balloon occlusion were 
dichotomised into positive or negative (table 2) according 
to the predetermined cutoff of 2·947 nu. The sensitivity 
for the target conditions was 0·87 (55 of 63; 95% CI 
0·77–0·93) for acute coronary artery occlusion, 0·95 
(54 of 57; 0·86–0·98) for acute coronary artery occlusion 
with ECG changes, and 1·00 (35 of 35) for acute coronary 
artery occlusion with ECG changes and STEMI criteria. 
Additionally, the index test was more sensitive to detect a 
60 s acute coronary artery occlusion than the STEMI 
criteria on 12-lead ECG (87% vs 56%; paired comparison 
with McNemar test p<0·0001).
The proportion of total variation in study estimates due 
to heterogeneity between patients (I²) was low (12·6%). 
The mean false positive rates in clinical subgroups 
according to age, sex, body-mass index, and abnormal 
QRS is summarised in figure 4 and revealed no subgroup 
with a significantly different mean false positive rate. 
The algorithm triggered a repeat recording if a positive 
result (n=213) was detected. 160 (75%) of these false 
positive recordings triggered a repeated recording 
effectively within 5 min. 109 (68%) of these repeated false 
positive recordings were normal within 5 min.
The accuracy of self-recordings at other cutoff values is 
presented in the empirical ROC calculated with the 
3873 recordings without acute coronary artery occlusion 
and the 63 index recordings with acute coronary artery 
occlusion (appendix). The area under the ROC curve was 
0·973 (95% CI 0·956–0·990). No patients died during 
the study.
Discussion
In our multicentre, observational study, we found that 
the use of our RELF device for self-detection of acute 
coronary artery occlusion was feasible, with high 
sensitivity and specificity. Patient and system delay in 
reperfusion strategies highlight the need for a rapid rule-
in tool (ie, a tool that rapidly confirms acute coronary 
artery occlusion) to guide patients at risk of acute 
coronary artery occlusion towards optimal decision 
making, without overloading emergency services. To our 
knowledge this is the first clinical study of an automatic 
handheld device for self-detection of acute coronary 
artery occlusion.7
We found that in the hands of patients with coronary 
artery disease our newly developed device is highly 
sensitive (0·87) and specific (0·958) for detecting acute 
coronary artery occlusion at 60 s of onset. This early stage 
of acute coronary artery occlusion was simulated by 60 s 
of coronary balloon occlusion. Of interest, at 60 s of 
occlusion our device was more sensitive than the current 
STEMI criteria on 12-lead ECG (87% vs 56%).
We documented that self-applications are operationally 
feasible (91%) for a broad range of patients with coronary 
artery disease, provided patients have a basic knowledge 
of smartphone use and absence of cardiac implantable 
electronic devices or left bundle branch block at baseline. 
The presence of left bundle branch block with QRS more 
than 150 ms is automatically detected at intake by the 
RELF device and these patients are automatically 
excluded from further recordings.
Our device might be suitable both for use in trials and 
in clinical practice. The high sensitivity and specificity of 
the current device suggest that it might serve in trials as 
the gold standard for early detection of ECG evidence of 
STEMI, allowing comparison with novel devices. 
However, the main purpose of the device will be everyday 
application by patients with 0·5% annual risk of 
symptomatic acute coronary artery occlusion, such as 
patients with multiple risk factors for coronary artery 
disease, patients with proven coronary artery disease, or 
patients during 6 months after a first unexplained chest 
pain episode. The device consists of a sensor part, 
connected via Bluetooth to a medical app on a smartphone. 
The sensor part, as used in our study, is operationally 
feasible and can be even further reduced in size and 
weight. It can remain in the patients’ pockets or in their 
vicinity and be applied on the body any time when in 
doubt about ongoing chest pain (see online video, 
appendix). After taking some reference recordings 
(ideally 13), the app is ready for use and can be applied at 
any time. A checklist of the story table is provided in the 
appendix.
Invasively placed intracardiac ischaemia monitors have 
been developed for earlier identification of ischaemia in 
patients with a high risk of acute coronary syndrome and 
alert patients of a potential occlusive event. These devices 
might be beneficial among high-risk patients for 
potentially identifying asymptomatic ischaemic events.13 
Handheld devices and implantable intracardiac ischaemia 
monitors might be complimentary solutions to reduce 
Figure 4: Mean false positive rates of RELF measurements in predefined subgroups
Rates are presented with 95% CIs and were similar between subgroups. *12 cases without false positive recordings 
were given one false positive recording and their sample size was increased with one to allow calculation of the 
weighted individual contributions.
Sex
Female
Male
Age (years)
<60
60–70
>70
Body-mass index (kg/m2)
<26
26–30
>30
QRS
Normal
Abnormal
All random effect
Sample (n/N*)
 75/1180
 150/2642
 78/1242
 84/1506
 63/1074
 62/985
 113/1909
 50/928
 141/2609
 84/1213
 225/3822
Effect size (SE; 95% CI)
4·94%
4·20%
4·19%
4·37%
4·94%
4·22%
3·57%
4·01%
3·89%
3·67%
4·19%
(0·010;
(0·006;
(0·009;
(0·008;
(0·010;
(0·007;
(0·006;
(0·008;
(0·005;
(0·007;
(0·005;
2·93–6·94)
3·07–5·33)
2·44–5·94)
2·76–5·99)
2·93–6·95)
2·77–5·68)
2·46–4·68)
2·40–5·62)
2·96–4·82)
2·35–5·00)
3·29–5·10)
2 3 4 5 6 7
Mean false positive rate (%)
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patient delay. Handheld devices are targeted for a large 
population with low or moderately increased risk of an 
acute coronary artery occlusion, whereas the implantable 
monitors are targeted for more select patients at very high 
risk of acute coronary artery occlusion14 or who have an 
additional indication to implant an intracardiac device.15
A tool to guide patients with acute coronary artery 
occlusion towards immediate and safe transport (by 
emergency services and guarded by an external 
defibrillator) to the catheterisation laboratory could have a 
substantial effect on mortality of patients with acute 
coronary artery occlusion.2,4 A rapid rule-in tool, to rapidly 
confirm acute coronary artery occlusion, should not 
overload emergency departments, which could theoret-
ically occur when the positive predictive value of the test 
in the target population is less than the current probability 
of acute coronary artery occlusion in patients visiting the 
emergency department for chest pain. The probability of 
acute coronary syndrome in patients visiting the 
emergency department for chest pain varies between 3% 
and 25%.16–20 The (pretest) empirical and theoretical 
probability for acute coronary syndrome during chest 
pain in a general population has been estimated to be 
2–12%. The theoretical probability is based on the 
proportion of annual risk of acute coronary artery 
occlusion (44–142 per 100 000 per year)21 and annual risk 
of chest pain in the general population (1–2% of 
adults).22–24 Indeed, of 1212 consecutive patients with chest 
pain, aged 35 years and older, attending 74 general 
practitioners, 3·6% presented with acute coronary 
syndrome.25 In a general practice setting in the Flemish 
part of Belgium, significant heart disease was present in 
only 5% of the chest pain patients.26 Of 172 180 patients 
who presented with a first consultation for chest pain to 
223 general practices in the UK, 4·8% were attributed to 
coronary artery diease.23 With the confidence intervals of 
sensitivity and specificity from our study and an a priori 
risk of acute coronary artery occlusion for a patient with 
chest pain in the general population between 2 and 12%, 
the positive predictive value for acute coronary artery 
occlusion will be 0·573 (95% CI 0·352–0·718; Monte Carlo 
simulation), far exceeding the current probability of acute 
coronary syndrome in patients visiting the emergency 
department for chest pain. The positive and negative 
predictive values for different risk categories are given in 
table 3. Our device could be useful and economically 
beneficial for patients with more than 0·5% annual risk 
for acute coronary artery occlusion, such as patients with 
proven coronary artery disease, patients with recent stent 
implantation, or patients with unexplained chest pain.23 
These patients could carry our device and electrodes in 
their pocket or have them constantly in their vicinity to 
self-apply the RELF method immediately during acute 
symptoms to avoid delay in case of acute coronary artery 
occlusion.
We have previously discussed why the RELF method 
outperforms other ECG methods to detect acute coronary 
artery occlusion.8 In brief, the RELF method has been 
developed to be very sensitive for ST deviations 
perpendicular to the long axis of the left ventricle because 
these are typically associated with acute coronary artery 
occlusion (transmural ischaemia). The RELF method is 
less sensitive for ST deviations parallel to the long axis of 
the left ventricle, which are typically associated with 
subendocardial or non-transmural ischaemia and with 
more physiological shifts in ST segment, such as those 
related to changes in heart rate or body position. Holter 
devices and exercise stress treadmills have robust and 
extensively validated algorithms to detect ST segment 
deviations but are not designed for self-application and do 
not specifically target ST changes perpendicular to the 
long axis of the left ventricle. Therefore, these tests might 
be less sensitive and specific for the minimal ST changes 
related to the early phase of acute coronary artery 
occlusion.
Self-applications of the RELF method applied in our 
device preserve their accuracy for several reasons. First, 
the lead system is easy to apply and designed for on-
demand self-application of electrodes, preventing 
electrode switching, or bad positioning. Specifically, the 
application of the E lead on the chest is guided by the 
lead design in a way that deviation of more than 3 cm 
from the target position is avoided (appendix). Second, 
the automated ECG quality algorithm (appendix) rejects 
self-recordings with baseline wandering or muscle 
activity (8·9% of home recordings) and immediately 
requests a new recording. Furthermore, the algorithm 
allows a minimum of signal filtering to preserve the 
characteristics of the ST segment that could otherwise be 
obscured by the use of high pass and low pass filters or 
filters in the frequency domain of the ST segment.27–29 
When the device is used on a larger scale during normal 
physiological conditions, it might be possible to further 
lower the detection threshold of the algorithm according 
to patient specific characteristics.
Annual risk for 
symptomatic 
acute coronary 
artery occlusion
Positive predictive 
values
Negative predictive 
values
Adult population 0·05–0·15% 57·3% (35·2–71·8) 99·1% (98·0–99·8)
ASCVD score >20 0·5–1·0% 91·0% (85·3–94·7) 93·5% (87·2–98·4)
Stable multivessel coronary artery 
disease
0·5–1·0% 91·0% (85·3–94·7) 93·5% (87·2–98·4)
Stent implantation <1 year 0·5–1·0% 91·0% (85·3–94·7) 93·5% (87·2–98·4)
Unexplained chest pain <6 months23 0·5–1·0% 91·0% (85·3–94·7) 93·5% (87·2–98·4)
Recent acute coronary syndrome 
<1 year
1·5–3·0% 96·8% (94·8–98·2) 83·1% (69·2–95·6)
Complex stenting <1 year 1·5–3·0% 96·8% (94·8–98·2) 83·1% (69·2–95·6)
Data are % or % (95% CI). The Monte Carlo simulations (n=10 000) are based on the 95% CIs for sensitivity and 
specificity and on the estimated incidence of chest pain without acute coronary artery occlusion between 1% and 2%21–23 
in all risk categories. ASCVD score=10-year risk for atherosclerotic cardiovascular disease in adults aged 40–79 years. 
Table 3: Positive and negative predictive values for the RELF test when the device would be used during 
chest pain or discomfort in a priori-defined risk categories for acute coronary artery occlusion
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One criterion for patients to be excluded from the study 
was the inability to use a mobile phone or smartphone in 
the past month. More specifically, the necessary skills 
were handling (reading and touching) an interface on a 
touch screen to start a recording and to read the result 
and attaching wired electrodes to the skin according to 
an instruction folder consisting of six steps on one page. 
The technical skills needed to use the study version of 
this technology are presented in a video in the appendix. 
To allow maximum participation we thought that the 
ability to use a mobile phone or smartphone in the past 
month was an appropriate wording to condense the 
two necessary skills.
We did not assess the associations between patient 
characteristics and the proportion of quality rejected 
recordings, which could be helpful in finding potentially 
unknown determinants of quality rejected recordings 
other than electrode–skin contact noise and noise from 
muscle activity.
The RELF algorithm alerts patients to a potential acute 
coronary artery occlusion by applying a single cutoff of 
2·947 nu, which is based on the 95th percentile of the 
measurements during normal physiological conditions 
in our previous study.8 We assume that the changes of the 
ST vectors induced by acute coronary artery occlusion are 
not specific to individual patients but are inherent to the 
acute coronary artery occlusion. Conversely, the variations 
of the ST vectors induced by normal physiological 
conditions are probably patient specific; if these variations 
are large and overrule those induced by acute coronary 
artery occlusion, then the sensitivity will be compromised. 
From a clinical point of view, we would not increase the 
cutoff at the expense of sensitivity. However, if the 
variations between patients are small, then indeed there 
would be an opportunity to lower the cutoff and thereby 
increase the sensitivity.
The algorithm calculates an individualised ST reference 
vector based on the average of the most recent 13 reference 
measurements in asymptomatic daily life conditions. In a 
theoretical study (unpublished) we assessed the effect of 
increasing the number of reference recordings on the 
95th percentile of STDVn and documented that generating 
more than 13 reference recordings did not further reduce 
the 95th percentile of STDVn.
Any tool to guide patients at risk for acute coronary 
artery occlusion should start with the advice that 
whenever the patient feels the need for medical help 
during chest pain or discomfort, they should not hesitate 
and seek immediate medical attention without consulting 
any device. A device such as ours should only be used by 
patients with chest pain or discomfort who are in doubt 
for seeking immediate medical help. Such a device should 
also, in case of absence of ST elevation, further guide the 
patient with a non-ST segment elevation myocardial 
infarction or non-coronary cause of ongoing chest pain. 
These patients generally have a much lower risk of out-of-
hospital ventricular fibrillation or irreversible loss of 
myocardial viability than those with acute coronary artery 
occlusion. The device will automatically generate 
messages on the screen of the device, such as seek 
medical attendance within two hours from now or seek 
medical attendance within 12 hours from now. The built-
in algorithm will follow either an anticipatory plan from 
the health-care provider5 or guidelines on chest pain 
management. An example of such an algorithm is 
included in the appendix.
Because the use of our device must be initiated before 
an expected clinical event, we will need a larger sample 
size to capture real-world events, such as ongoing chest 
pain or myocardial infarction. To assess whether the 
introduction of the RELF device in the management of 
coronary artery disease will effectively reduce patient and 
system delay, we have planned a randomised controlled 
trial of 5400 patients in 2020, when our device will be 
manufactured on a large scale. To obtain 80% power to 
detect an increase from less than 20% to more than 70% 
of the proportion with very short patient delay (<30 min), 
defined as time from onset of symptoms to emergency 
call, 1800 patients with coronary artery disease will be 
enrolled in the device empowerment group and 3600 in 
the advice control group. At that time, a medical graded 
mobile app on the patients’ smartphones will capture the 
data from the sensor and detect acute coronary artery 
occlusion according to our algorithm.
Our RELF device is, to our knowledge, the first validated 
device intended for automatic rapid rule-in during chest 
pain in patients with coronary artery disease. Self-
application is operationally feasible for most patients with 
coronary artery disease. The proof-of-concept is supported 
by its high sensitivity and specificity for detection of the 
earliest phase of acute coronary artery occlusion. Even if 
applied to populations with a low probability of acute 
coronary artery occlusion during chest pain (2–12%), the 
positive predictive value remains higher than the current 
probabilities in patients visiting the emergency depart-
ment with chest pain. Therefore, our study device fulfils 
all essential conditions to empower the patient with 
coronary artery disease towards more efficient use of 
emergency services for ongoing chest pain. This study 
further illustrates that digital automated interpretation of 
individual pre-event data enables precision diagnosis of 
new events.
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